Kodiak Sciences Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Obtains Global Rights To Hansoh’

Kodiak Sciences Inc. has shelved its lead candidate, tarcocimab, for wet age-related macular degeneration (AMD) and diabetic macular edema (DME) after two of a trio of Phase III trials failed, castin

Kodiak Sciences Inc. still has options for KSI-301, but they are narrower now that the Phase IIb/III DAZZLE study in wet age-related macular degeneration (AMD) failed to meet its primary endpoint of

Cytokinetics’ Omecamtiv For Heart Failure Cytokinetics, Inc. is expected to release top-line data from the Phase III METEORIC-HF study of omecamtiv mecarbil, a selective cardiac myosin activator, by